01-02-09
New Drug
Application Submitted
for Acurox® Tablets
12-24-08
King
Pharmaceuticals Exercises
Option to
License Fourth Opioid Product from Acura Pharmaceuticals
10-27-08
Acura
Pharmaceuticals, Inc.
Reports
Results for Q3-08
10-13-08
Acura
Pharmaceuticals and King
Pharmaceuticals Announce Positive Top LIne Results of Key Clinical Study
Assessing Abuse Liability - Acurox™
Tablets Significantly Disliked When Excess Doses Are Swallowed
10-10-08
Acura
Pharmaceuticals, Inc. to Present at NATIXIS Bleichroeder Hidden Gems
Conference
09-02-08
Acura
Pharmaceuticals, Inc.
Announces
Return of President and CEO From Medical Leave
07-30-08
Acura
Pharmaceuticals, Inc.
Reports
Results for Q2-08
07-21-08
Acura
Pharmaceuticals, Inc. Announces Action Regarding Notice of Allowance
Received for Second Aversion® Technology Patent
06-30-08
Acura
Pharmaceuticals, Inc. Receives $5.0 Million Milestone Payment
06-30-08
Acura
Pharmaceuticals, Inc. Added to the Russell 3000® Index and the Russell
Microcap® Index
06-17-08
Acurox
Tablets™
Meet Primary Endpoint in Pivotal Phase III Study
06-03-08
Acura
Pharmaceuticals, Inc. Announces Notice of Allowance for Second Aversion® Technology
Patent
06-02-08
Acura
Pharmaceuticals, Inc. Announces Active IND for Second Opioid Analgesic
Product Candidate
Using Aversion® Technology
05-27-08
King
Pharmaceuticals Exercises Option to License Third Opioid Product
Utilizing Acura's Aversion® Technology
04-30-08
Acura
Pharmaceuticals, Inc.
Reports
Results for Q1-08
04-24-08
King
Pharmaceuticals and Acura
Pharmaceuticals Announce Completion of Patient Enrollment for Pivotal
Phase III Clinical Trial Evaluating Acurox™
03-24-08
Acura
Pharmaceuticals, Inc. Names Robert B. Jones Chief Operating Officer
03-05-08
Acura
Pharmaceuticals, Inc. Reports 2007 4th Quarter and Annual Financial
Results; Sets 2008 Expectations
02-27-08
Acura
Pharmaceuticals, Inc. Announces Andrew Reddick, President & CEO, to take
Medical Leave and Appointment of Richard Markham as Chairman of the
Board
01-31-08
Acura
Pharmaceuticals, Inc. Announces Approval To List Shares on NASDAQ and
Effective Feb. 4, 2008, a New Trading Symbol: ACUR
01-24-08
Acura
Pharmaceuticals, Inc. Announces Appointment of George K. Ross as
Director
12-10-07
Acura
Pharmaceuticals, Inc. Announces Receipt of $30 Million Cash Payment and
Closing of Agreement with King Pharmaceuticals
12-04-07
Acura
Pharmaceuticals, Inc. Announces Implementation of Reverse Stock Split
and New Trading Symbol: ACPH.OB
11-02-07
Acura
Pharmaceuticals, Inc. Reports Results for Q3-07
10-31-07
King
Pharmaceuticals and
Acura
Pharmaceuticals enter Agreement to Develop and Commercialize Immediate
Release Pain Medicines Utilizing Acura's Aversion®
(Abuse-Deterrent) Technology
